Pfizer 2009 Annual Report Download - page 29

Download and view the complete annual report

Please find page 29 of the 2009 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 110

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110

Financial Review
Pfizer Inc. and Subsidiary Companies
We no longer are seeking approval in the EU for Celsentri (maraviroc) for the treatment of HIV in treatment-naïve patients. Celsentri
(maraviroc) remains approved in the EU for use in combination with other antiretroviral medicinal products for treatment-experienced
adult patients with only CCR5-tropic HIV-1 detectable.
Late-stage clinical trials for additional uses and dosage forms for in-line products:
PRODUCT INDICATION
Celebrex Acute gouty arthritis
Eraxis/Vfend Combination Aspergillosis fungal infections
Lyrica Epilepsy monotherapy; post-operative pain; restless legs syndrome; central neuropathic pain due to
spinal cord injury; peripheral neuropathic pain
Macugen Diabetic macular edema
Prevnar/Prevenar 13 Adult Prevention of invasive pneumococcal disease in adults
Revatio Pediatric pulmonary arterial hypertension
Sutent Breast cancer; non-small cell lung cancer; prostate cancer; liver cancer
Zithromax/chloroquine Malaria
In early 2009, we had four Phase 3 studies evaluating Sutent for the treatment of advanced breast cancer. In March 2009, we
discontinued a Phase 3 trial of single-agent Sutent versus Xeloda (capecitabine) for treatment of advanced breast cancer. In June
2009, we discontinued another Phase 3 trial that compared Sutent plus Taxol (paclitaxel) to Avastin (bevacizumab) plus Taxol for
first-line treatment of advanced breast cancer. Both studies were discontinued due to futility. We continue to study Sutent for
treatment of advanced breast cancer in two other Phase 3 trials, which have completed enrollment. In June 2009, we discontinued a
Phase 3 trial of Sutent for first-line treatment of metastatic colorectal cancer due to futility.
New drug candidates in late-stage development in the U.S.:
CANDIDATE INDICATION
Apixaban For acute coronary syndrome, the prevention and treatment of venous thromboembolism and
prevention of stroke in patients with atrial fibrillation, which is being developed in collaboration with
BMS
Axitinib A multi-targeted kinase inhibitor for the treatment of renal cell carcinoma
Bapineuzumab A beta amyloid inhibitor for the treatment of Alzheimer’s disease being developed in collaboration
with Janssen Alzheimer Immunotherapy Research & Development, LLC, a subsidiary of Johnson
& Johnson
Bazedoxifene-conjugated
estrogens (Aprela)
A tissue selective estrogen complex for the treatment of menopausal vasomotor symptoms
Bosutinib An src kinase inhibitor for the treatment of chronic myelogenous leukemia
Figitumumab (CP-751871) An anti-insulin-like growth factor receptor 1 (IGF1R) human monoclonal antibody for the treatment of
non-small cell lung cancer
Latrepirdine (Dimebon) A novel mitochondrial protectant and enhancer being developed in partnership with Medivation for
the treatment of Alzheimer’s disease and Huntington’s disease
Moxidectin Treatment of onchocerciasis (river blindness)
Neratinib A pan-HER inhibitor for the treatment of breast cancer
PF-02341066 An oral c-Met and ALK inhibitor for the treatment of advanced non-small cell lung cancer
PF-0299804 A pan-HER tyrosine kinase inhibitor for the treatment of lung cancer
Tanezumab An anti-nerve growth factor monoclonal antibody for the treatment of pain
Tasocitinib (CP-690,550) A JAK-3 kinase inhibitor for the treatment of rheumatoid arthritis
In December 2009, we discontinued a Phase 3 trial of figitumumab in first-line treatment of non-small cell lung cancer for futility. We
continue to study figitumumab in 2nd/3rd line treatment in another Phase 3 trial, and an additional Phase 3 trial in first-line treatment is
in the planning stage.
The Phase 3 clinical trial of apixaban for the prevention of stroke in patients with atrial fibrillation, a potentially significant indication,
is event driven. As such, it is not possible to predict with certainty when the results of this trial will be available. BMS currently
expects to have data from this trial in mid-2011 and to file for U.S. regulatory approval for this indication later in 2011 depending on
the results of the trial.
In December 2009, we completed our sale of Vicuron, including dalbavancin for skin and skin structure infections, which is currently
in Phase 3 development, to Durata Therapeutics.
2009 Financial Report 27